Rated 5.00 out of 5 based on 1 customer rating
(1 customer review)



Buy ADB-FUBINACA 10g is a designer drug identified in synthetic cannabis blends in Japan in 2013.

The (S) enantiomer of ADB FUBINACA 10g is claimed in Pfizer patent WO 2009/106982 and has been reported to be a potent agonist of the CB1 receptor and CB2 receptor with an EC50 value of 1.2 nM and 3.5 nM respectively.

ADB FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135.

ADB FUBINACA appears to be the product of rational drug design, since it differs from AB-FUBINACA only by the replacement of the isopropyl group with a tert-butyl group.

An analogue of ADB-FUBINACA, ADSB-FUB-187, containing a more functionalized carboxamide substituent was recently reported.

One death through coronary arterial thrombosis has been linked to ADB FUBINACA intoxication.

At least an additional 8 deaths in Hungary in 2015 are linked to the usage of this material, all deaths were younsgters below 21.

Twenty-three ADB-FUBINACA major metabolites were identified in several incubations with cryopreserved human hepatocytes.

Major metabolic pathways were alkyl and indazole hydroxylation, terminal amide hydrolysis, subsequent glucuronide conjugations, and dehydrogenation.

1 review for ADB-FUBINACA 10g

  1. Rated 5 out of 5

    John Medona

    good work

Add a review

Your email address will not be published. Required fields are marked *

WhatsApp chat